NASDAQ : LFMD

LifeMD, Inc. — News

$3.73 USD

$0.23 (6.57%)

Volume
596.51K
Average Volume
942.1K
Market Capitalization
$180.39M
P/E Ratio
-9.05
Dividend Yield
0.00%
Price Target
$10.00
Year High
$12.72
Year Low
$2.56
Day High
Day Low
Payout Ratio
-$0.19
Current Ratio
$1.04
Source Headline
Critical Survey: Ryman Healthcare (OTCMKTS:RYHTY) vs. LifeMD (NASDAQ:LFMD)

LifeMD (NASDAQ: LFMD - Get Free Report) and Ryman Healthcare (OTCMKTS:RYHTY - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares LifeMD and

defenseworld.net - 2026-07-30 01:59:00

LifeMD to Report Second Quarter 2026 Financial Results on August 5

NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on August 5, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time.

globenewswire.com - 2026-07-24 16:05:00

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2026, to holders of record at the close of business on July 3, 2026.

globenewswire.com - 2026-06-23 08:00:00

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July 2026 in 37 states

globenewswire.com - 2026-06-22 08:00:00

LifeMD Appoints Umesh Sripad as Chief Technology Officer

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Umesh Sripad as Chief Technology Officer (CTO), effective immediately. In this role, Mr. Sripad will lead LifeMD's technology strategy, platform transformation, AI enablement, cybersecurity, data infrastructure, and enterprise scalability initiatives as the company continues its rapid expansion.

globenewswire.com - 2026-06-01 08:05:00

LifeMD Appoints Umesh Sripad as Chief Technology Officer

Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD's Next Phase of Growth Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD's Next Phase of Growth

globenewswire.com - 2026-06-01 08:05:00

LifeMD to Participate in Upcoming Investor Conferences

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming investor conferences.

globenewswire.com - 2026-05-15 08:00:00

LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript

LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 23:01:15

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.01 per share a year ago.

zacks.com - 2026-05-06 19:35:41

LifeMD Reports First Quarter 2026 Results

First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company's guidance. Gross margin increased approximately 420 basis points to 88%, versus the first quarter of 2025, reflecting favorable revenue mix and lower fulfillment costs.

globenewswire.com - 2026-05-06 16:05:00

Get LFMD Insider Trade Alerts

LFMD Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$10.00

1 analysts

Last Year

$8.67

6 analysts

All Time

$10.85

13 analysts

LFMD Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-05-26 HC Wainwright & Co. Maintain Buy Buy
2026-05-04 BTIG Maintain Buy Buy
2026-03-16 Mizuho Upgrade Neutral Outperform
2026-03-12 Freedom Broker Maintain Buy Buy
2026-03-12 Freedom Capital Markets Maintain Buy Buy
2026-03-11 HC Wainwright & Co. Maintain Buy Buy
2026-03-10 BTIG Maintain Buy Buy